US Bancorp DE lessened its stake in shares of Gorman-Rupp (NYSE:GRC) by 3.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 136,614 shares of the industrial products company’s stock after selling 5,085

Best Gold Stocks To Own For 2017

Earlier this week, Simon Chiu watched Snapchat’s team put on an IPO presentation for investors in San Francisco. He was surrounded by investment bankers from firms like Morgan Stanley and Goldman Sachs.

“It was a little bit of fish out of water for me,” Chiu told CNNTech. “I’m an educator. It’s not what I do.”

Chiu is the president of Saint Francis High School in Mountain View, California. The Catholic school just happens to be one of the first investors in Snapchat (SNAP).

Five years ago, Saint Francis invested $15,000 in Snapchat. After the company’s blockbuster public offering Thursday, that stake is likely worth millions.

The unusual deal came about thanks to a few students who were obsessed with the app — and one curious parent who happened to be a venture capitalist.

Barry Eggers, founder of Lightspeed Venture Partners, came home from work one day to find his daughter Natalie and her friends staring at their phones and laughin g.

Shares of Inovio Pharmaceuticals(INO) are climbing today after the biotech company announced that it would begin testing a Zika vaccine in Puerto Rico. Maxim’sJason McCarthy andJason Kolbert have the details:

CREDIT: Alex Wild Published Credit: Alex Wild Alex Wild

Inovio announced the initiation of a small clinical study (N=160) of its Zika vaccine, GLS-5700 (being developed with GeneOne Life Sciences), in Puerto Rico. It is estimated by the CDC that the Zika virus could infect more than 25% of the population of Puerto Rico by YE16.The study will evaluate safety, immunogenicity and early signs of efficacy in preventing Zika infection. Data are expected in 2017, and if positive, Inovio will discuss with regulators the best path forward.

In addition, the phase I study of GLS-5700 (N=40) in the U.S. and Canada, which is the first in-human Zika vaccine study, is now fully enrolled. Data evaluating safety and immunogenicity are expected by YE16.

Conclusion. With the Zika virus spreading, including to the U.S., there remains an urgent need for a vaccine. Inovio continues to demonstrate that the company’s DNA-based vaccine approach is safe and can rapidly transition to human studies.

In a Private Briefing report in late July, we told you that tiny biotech Inovio Pharmaceuticals Inc. (Nasdaq: INO) had dosed its first patient in a Phase I clinical study to evaluate its synthetic vaccine for the Zika virus.

[By Keith Speights]

A quick analysis of Inovio Pharmaceuticals’ (NASDAQ:INO) stock performance history shows plenty of twists and turns — from the company’s early biomedical days to its recent advances in developing a Zika virus vaccine. But this chart shows the story hasn’t been great for investors.

* The market bent yesterday but today it stabilized. (A good showing, all things being considered–but in no way decisive going forward). * Gold +$5/oz. * Crude oil +$0.50 and the rise is taking up some energy stocks. * The Russell returned to the spotlight. * Life insurance–particularly Lincoln National (LNC) (on an upgrade). Hartford Financial Services (HIG) gets a small lift. * Retail returned from the depths. The standouts–L Brands (LB) , Kohl’s (KSS) , Bed Bath (BBBY) , Nordstrom (JWN) and Gap (GPS) . * Ag equipment–after an analyst upgrade yesterday. * Brokerages. * Homebuilders catch a bid. * Day one of the Masters Golf Tournament.

[By Lee Jackson]

Lincoln National Corp. (NYSE: LNC) also had the man at the top selling stock last week. Dennis Glass, the CEO of this insurance and retirement focused company, sold a block of 75,000 shares at between $71.00 and $71.28 apiece. The total for the sale was posted at $5 million. Shares closed Friday at $71.69, in a 52-week rangeof $34.16 to $73.71. The consensus price target is $73.17.

On a market cap weighted basis,Wal-Mart trades at a discount to the average of a group of large-cap consumer staples companies (Coca-Cola (KO), PepsiCo (PEP), Newell Brands (NWL), Procter & Gamble (PG), and Colgate-Palmolive (CL) – covered by Morgan Stanley Analyst Dara Mohsenian). Wal-Mart’s FTM relative P/E multiple is currently 0.76x vs. the 0.89x average over the last 15 years.

ValueAct, a successful activist fund, has built a $1.2 billion stake in Citigroup (C). According to the WSJ it suggested Citigroup could boost its buyback plan from $40 to $50 billion. With a market cap of $185 billion that's a large percentage of stock to take out. Buyback programs of this relat

US Bancorp DE lessened its stake in shares of Gorman-Rupp (NYSE:GRC) by 3.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 136,614 shares of the industrial products company’s stock after selling 5,085

The age of hybrid-electric commercial aircraft is right around the corner. A start-up backed by Boeing (NYSE:BA) just hit an important milestone in its quest to be among the first to cash in on the technology.

On May 21, Zunum Aero signed a deal to sell up to 100 of its electric-powered p

CGI Group (NYSE: GIB) and Information Services Group (NASDAQ:III) are both computer and technology companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and in

What would a dividend investor's dream stock look like? The obvious characteristic would be a high dividend yield. Of course, the dividend also would need to be one that's both sustainable and growing.

It also would be great if the underlying business was rock-solid with a strong competi